How Molecular Profiling Guides Medical Treatment

ESGO eAcademy, Domenica Lorusso, 411107

Efficacy And Safety Of Bevacizumab Following Prior Anti-Angiogenic Treatment In Patients With Second-Line Platinum- Based Chemotherapy In Recurrent Ovarian Cancer – A Subgroup Analysis Of The AGO-OVAR 2.21 Phase III Trial

ESGO eAcademy, Chelariu-Raicu Anca, 411102

Multi-Omic Characterization Of Naïve Treatment Samples Of Epithelial Ovarian Cancer Addressed To Neoadjuvant Chemotherapy: An Hypothesis-Generating Study On Biomarkers Of Response To Platinum-Based Chemotherapy

ESGO eAcademy, Camilla Nero, 411100

Indication of Adjuvant or Peri Operative Therapy for LMS and other HG Uterine Sarcoma

ESGO eAcademy, Paolo Casali, 411109

The New FIGO Staging in the Modern Era of Molecular Profiling

ESGO eAcademy, Nicole Concin, 411106

Survival Outcomes Following Cytoreductive Surgery In Advanced Ovarian Cancer Patients: Prognosis Is Better Predicted By Completeness Of Resection Than By Disease Stage

ESGO eAcademy, Ioannis Kotsopoulos, 411099

Peritonectomy And Resection Of Mesentery During Visceral-Peritoneal Debulking (VPD) In Patients With Stage IIIC-IV Ovarian Cancer: A Phase I-II Trial

ESGO eAcademy, Matteo Marchetti, 411098

Molecular Profiling in Endometrial Cancer: Pitfalls and Challenges

ESGO eAcademy, Xavier Matias-Guiu, 411105

Principle of the Surgery in First Line and Relapse for Uterine Sarcoma

ESGO eAcademy, Jalid Sehouli, 411108

ESGO Gynae-Cancers Algorithms App Presentation

ESGO eAcademy, Richard Schwameis, 411096

Impact Of BRCA Mutation Status On Efficacy Of Atezolizumab Combined With Platinum-Based Chemotherapy And Maintenance Niraparib For Late-Relapsing Recurrent Ovarian Cancer: Subgroup Analysis Of The ENGOT-Ov41/GEICO 69-O/ANITA Phase 3 Trial

ESGO eAcademy, Michel Fabbro, 411088

Variant Histology Cervical Cancer: Approach to Definitive Radiation Therapy

ESGO eAcademy, Marisa Kollmeier, 411095

Vascular Challenges in Minimally Invasive Surgery

ESGO eAcademy, Reitan Ribeiro, 411092

Senaparib Maintenance In Newly Diagnosed Advanced Ovarian Cancer: FLAMES Study

ESGO eAcademy, Xiaohua Wu, 411087

Discussant - Leuven PARP i Benefit Test

ESGO eAcademy, Gourley Charlie, 411086

How Clinical Management Guidelines Deviate from Common Tumour Types

ESGO eAcademy, David Cibula, 411094

The Leuven PARPi Benefit Test As Improved Approach For Prediction Of PARPi Benefit In The PAOLA-1/ENGOTov25 Trial

ESGO eAcademy, Liselore Loverix, 411085

How We Prevent and Repair Vascular Complications?

ESGO eAcademy, José Ignacio Lorenzo, 411090

Assessment Of The Prognostic Impact Of The European Society Of Gynecologic Oncology Quality Indicators For Advanced Ovarian Cancer Surgery

ESGO eAcademy, Ane Gerda Z Eriksson, 411083

HPV Independent Tumours - Recent Developments from a Pathologist´s Perspective

ESGO eAcademy, Simona Stolnicu, 411093

ADC Resistance

ESGO eAcademy, Toon Van Gorp, 411076

Updates in Pelvic and Urinary/Bowel Reconstruction after Pelvic Exenteration

ESGO eAcademy, Martina Angeles, 411079

How Should We Treat Rrecurrent LGSOC?

ESGO eAcademy, Susana Banerjee, 411082

Indication and Surgical Technique for LEER and Laterally Extended Pelvic Resection

ESGO eAcademy, Gwenael Ferron, 411078

Adjuvant Therapy Decision Making for IGSOC

ESGO eAcademy, Gourley Charlie, 411081

Immunotherapy Resistance

ESGO eAcademy, Iain Mcneish, 411074

Surgical Considerations for LGSOC

ESGO eAcademy, David Gershenson, 411080

From the Past to the Current Indications to Pelvic Exenteration

ESGO eAcademy, Nicolo Bizzarri, 411077

Modified Minimally Invasive Versus Open Radical Hysterectomy In Early-Stage Cervical Cancer: Interim Analysis Of A Multicenter, Prospective, Randomized Controlled Clinical Trial.

ESGO eAcademy, Tao Zhu, 410999

Cost-Effectiveness Analysis Of Simple Hysterectomy Compared To Radical Hysterectomy For Early Cervical Cancer From The CCTG CX.5 “SHAPE” Phase III Clinical Trial

ESGO eAcademy, Kwon Janice, 411073

Real-World Impact Of Surgical Clinical Trials In Gynecological Oncology: An Interrupted Time Series Analysis In France

ESGO eAcademy, Floriane Jochum, 411072

Value Of FDG-PET/CT For Staging Of Locally Advanced Cervical Cancer

ESGO eAcademy, Marc Barahona, 411071

Surgery-Class D Radical Hysterectomy

ESGO eAcademy, David Cibula, 411065

Updates of Recent Clinical Trials that Have Changed Our Disease Management: Cervical cancer

ESGO eAcademy, Mansoor Raza Mirza, 411062

Health-Related Quality Of Life In Patients With FRa Positive Platinum-Resistant Ovarian Cancer Treated With Mirvetuximab Soravtansine Vs. Investigator’s Choice Chemotherapy: Analysis From The Phase 3 MIRASOL Trial

ESGO eAcademy, Yolanda Garcia Garcia, 411070

The Role Of VY Flap Reconstruction In Vulvar Cancer Patients: A Multicenter Retrospective Study

ESGO eAcademy, Tullio Golia D'Augè, 411069

Chemo-Concurrent Radiation Therapy

ESGO eAcademy, Marisa Kollmeier, 411064

Updates of Recent Clinical Trials that Have Changed Our Disease Management: Endometrial cancer

ESGO eAcademy, Christian Marth, 411061

Three-Dimensional Transvaginal Ultrasound Vs Magnetic Resonance Imaging For Preoperative Staging Of Deep Myometrial Invasion In Patients With Endometrial Cancer: A Preliminary Results.

ESGO eAcademy, Giulia Spagnol, 411068

Exploring The Influence Of Volume Center On Surgical Outcomes In The Management Of Early-Stage Endometrial Cancer: A Subanalysis Of The SENECA Study.

ESGO eAcademy, Felix Boria, 411067

NACTH

ESGO eAcademy, sudeep gupta, 411063

Updates of Recent Clinical Trials that Have Changed Our Disease Management: Ovarian Cancer

ESGO eAcademy, Nicoletta Colombo, 411060

The Oncologic Outcomes Of Focal, Substantial, Or No Lymphovascular Space Invasion In Node Negative FIGO 2009 Stage I Endometrioid Endometrial Adenocarcinoma: A Multicenter Retrospective Cohort Study

ESGO eAcademy, Christian Dagher, 411066

Treatment Of Recurrent Inguinofemoral Lymphocele By ICG Mapping Of Lymphatic Leakage: A Case Report And Literature Review

ESGO eAcademy, Melanie Schubert, 411051

Still Looking for the Gear to Bring Immunotherapy in the Ovarian Cancer Treatment

ESGO eAcademy, Isabelle Ray-Coquard, 411054

Total Pelvic Exenteration In Recurrent Vulvar Cancer Step By Step

ESGO eAcademy, Sara Iacoponi, 411050

Total Pelvic Exenteration With Radical Vulvectomy And Anorectal Amputation In 10 Steps.

ESGO eAcademy, Elodie Gauroy, 411049

Have We Reached the Ceiling in the Treatment of Metastatic/Recurrent Cervical Cancer?

ESGO eAcademy, Ana Oaknin, 411053

Vulvo-Vaginal Reconstruction In Neoplastic Disease

ESGO eAcademy, Nadia Veiga Canuto, 411048

Pattern of Recurrence According to the Molecular Classification

ESGO eAcademy, Elisabeth Epstein, 411057

Leading a Paradigm Shift in the Treatment of Advanced/Recurrent Endometrial Cancer

ESGO eAcademy, Christian Marth, 411052

Composite Total Pelvic Exenteration In Vulvar Cancer Recurrence.

ESGO eAcademy, Sandra Flórez Herrero, 411047

Presentation of 1 Case Report

ESGO eAcademy, Alexandros Rodolakis, 411055

Laparoscopic En-Bloc Resection Of The Pelvis Sec. Hudson-DellePiane With Concomitant Rectosigmoid Anastomosis For Stage IIIC Ovarian Cancer

ESGO eAcademy, Orazio De Tommasi, 411040

Double Hepatic Segmentectomy Assisted With ICG For Recurrence Of Ovarian Cancer.

ESGO eAcademy, Sergi Fernández González, 411039

The NHS Jewish BRCA Testing Programme and General Population Panel Testing for Cancer Susceptibility Genes

ESGO eAcademy, Ranjit Manchanda, 411046

Robotic Sentinel Lymph Node Technique In Apparent Early Ovarian Cancer (ICG)

ESGO eAcademy, Victor Lago, 411038

False Hope for Cure May Prevent Shared Decision Making and End of Line Treatment in Line with Patient´s Preferences

ESGO eAcademy, Kristina Lindemann, 411043

How To Improve Bricker Ileal Conduit Functionality

ESGO eAcademy, Itziar Villagra, 411037

Implementing Jewish Population BRCA Testing in Israel

ESGO eAcademy, Ephrat Levy-Lahad, 411045

Lymph Node Recurrences In Ovarian Cancer: Safe Techniques In The Minimally Invasive Approach

ESGO eAcademy, SILVIO ANDREA RUSSO, 411036

How to Better Integrate the Opportunity to Access New Therapies Respecting a Quality of Life in Advanced Ovarian Cancer

ESGO eAcademy, Florence Joly, 411042

Compilation of Surgical Procedures for Upper Abdominal Debulking

ESGO eAcademy, Cagatay Taskiran, 411035

Population Based Risk Stratification for Breast Cancer Screening: Evidence Base and Future Directions.

ESGO eAcademy, Gareth Evans, 411044

Discussant

ESGO eAcademy, Paolo Casali, 411027

Primary Results Of DAYDREAM Study, A Real-World Multicentre Study On The Efficacy Of Adjuvant Chemotherapy In High-Grade Uterine Sarcomas

ESGO eAcademy, Alejandro Gallego Martínez, 411026

Rationalizing Gynaecological Reconstruction in an Algorithmic Approach Based on Anatomical Subunits

ESGO eAcademy, Stefano Gentileschi, 411034

Management of Recurrent OCCC

ESGO eAcademy, David Tan, 411031

Discussant

ESGO eAcademy, Christian Marth, 411025

Time To Deterioration Of Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy Compared With Chemotherapy In The ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

ESGO eAcademy, Ingrid Boere, 411024

Management of Newly Diagnosed Ovarian Clear Cell Carcinoma (OCCC)

ESGO eAcademy, Kosei Hasegawa, 411030

Current Approach to Secondary Lymphoedema on Gynaecological Cancer

ESGO eAcademy, Jaume Masia Ayala, 411033

Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab ± Olaparib As A First-Line Treatment For Newly Diagnosed Advanced Or Recurrent Endometrial Cancer: Results From The Phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

ESGO eAcademy, Marta Gil-Martin, 411023

Pathology and Molecular Features of Clear Cell Ovarian Carcinoma

ESGO eAcademy, Glenn McCluggage, 411029

Case Presentation: Case of 45-Year-Old with Newly Diagnosed Stage 3 Ovarian Clear Cell Carcinoma

ESGO eAcademy, Kosei Hasegawa, 411028

Taking the Reconstruction Elevator for Gynaecological Reconstruction

ESGO eAcademy, Jung-Ju Huang, 411032

Phase III Double-Blind Randomized Placebo Controlled Trial Of Atezolizumab In Combination With Carboplatin And Paclitaxel In Women With Advanced/Recurrent Endometrial Carcinoma: The Asian Cohort Of AtTEnd/ENGOT-EN7 Trial

ESGO eAcademy, Shin Nishio, 411022

Presidential Talk

ESGO eAcademy, Nicole Concin, 411021

Introduction of the ESGO president

ESGO eAcademy, Ignace Vergote, 411020

Understanding Endometrial Cancer from the Pathology Perspective

ESGO eAcademy, Xavier Matias-Guiu, 411019

Introduction and Announcement of the ESGO Helga Salvesen Translational and Clinical Research Award

ESGO eAcademy, Mansoor Raza Mirza, 411018

Advantages and Limitations of OSNA and Ultrastaging - The Pathologist’s Point of View

ESGO eAcademy, Xavier Matias-Guiu, 411017

OSNA for the Detection of SLN Metastases in Cervical Cancer - An Overview of the Performance and Survival Data

ESGO eAcademy, Francesco Fanfani, 411016

Effectivity of OSNA Method in Endometrial Cancer: A Large Retrospective Multicenter Study

ESGO eAcademy, Ignacio Zapardiel, 411015

Opening Remarks

ESGO eAcademy, Giovanni Scambia, 411013

Molecular Subgroups Versus Risk Of Sentinel Lymph Node Metastases And Recurrence In Endometrial Cancer

ESGO eAcademy, Lombaers Marike, 411003

Risk-Reducing Prophylactic Fimbriectomy Followed By Delayed Ooforectomy In Women At Risk Of Ovarian Cancer: Results Of A Single-Center Retrospective Analysis

ESGO eAcademy, Mathilde Duchatelet, 411002

Time Matters, Quality Makes The Most: The Experience Of An Italian Referral Center Including PALND In Treatment Algorithm For LACC

ESGO eAcademy, Elena Olearo, 411001

10 Years Of Double-Barrel Wet Colostomy: A Single-Institution’s Experience Performing An Alternative Diversion In Patients Undergoing Total Pelvic Exenteration For Gynecologic Malignancy

ESGO eAcademy, Maureen Byrne, 411000

Seneca Sentinel: Risk Factors For Unsuccessful Bilateral Sentinel Lymph Node Mapping In Endometrial Cancer

ESGO eAcademy, Felix Boria, 410998

Looking Beyond Immunotherapy in Endometrial Cancer: The Role of ADCs

ESGO eAcademy, Domenica Lorusso, 411006

Benefit From Atezolizumab In Patients With A Poor Prognostic Ovarian Cancer In First-Line Setting: IMAGYN-050 Trial

ESGO eAcademy, Benoit You, 410997

Cost-Effectiveness Analysis Of Cancer Susceptibility Gene-Specific Prevention Strategies For Ovarian And Breast Cancer

ESGO eAcademy, Xia Wei, 410996

Beating Metastatic/Recurrent Cervical Cancer through a Novel Therapeutic Approach, the ADCs

ESGO eAcademy, Ana Oaknin, 411005

Risk Factors For The Recurrence In Patients With Early Endometrioid Endometrial Cancer Achieving Complete Remission For Fertility-Sparing Hormonal Treatment

ESGO eAcademy, Jang Eun Bi, 410995

Risk Factors For The Recurrence In Patients With Early Endometrioid Endometrial Cancer Achieving Complete Remission For Fertility-Sparing Hormonal Treatment

ESGO eAcademy, Jang Eun Bi, 411790

The Application Value Of CDO1 And CELF4 Dual-Gene Methylation Testing In Screening For Endometrial Cancer In Women With Abnormal Uterine Bleeding

ESGO eAcademy, Bingxin Cai, 410994

Safety And Efficacy Of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) In Patients With Recurrent/Metastatic Cervical Cancer (RMCC) In The MOVIE Trial.

ESGO eAcademy, Jean-Sebastien Frenel, 410993

Expanding the Advanced Ovarian Cancer Treatment Landscape in the Relapse Setting

ESGO eAcademy, Jean Emmanuel Kurtz, 411004

Compliance With Follow-Up After Low-Grade Cervical Smear Results And The Long Term Risk Of Developing Cervical Cancer.

ESGO eAcademy, Ruud Bekker Bekkers, 410992